Stay updated with breaking news from Marks Levine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 8,960,000 shares, a growth of 5.3% from the April 15th total of 8,510,000 shares. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is […]
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) insider Mark S. Levine sold 2,134 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $36.15, for a total transaction of $77,144.10. Following the sale, the insider now owns 301,968 shares in the company, valued […]
Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Equities research analysts at HC Wainwright raised their FY2028 earnings per share estimates for shares of Immunovant in a research note issued to investors on Tuesday, February 13th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $2.16 for the year, […]
Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have received an average rating of “Buy” from the thirteen research firms that are currently covering the stock, Marketbeat Ratings reports. Thirteen equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued ratings on the […]
Immunovant (NASDAQ:IMVT – Free Report) had its target price hoisted by HC Wainwright from $29.00 to $47.00 in a report published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Immunovant’s Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.55) EPS, FY2024 […]